Jack Allen
Stock Analyst at Baird
(1.09)
# 3,509
Out of 4,670 analysts
41
Total ratings
32.35%
Success rate
-12.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INKT MiNK Therapeutics | Maintains: Outperform | $8 → $4 | $0.68 | +488.24% | 2 | Nov 15, 2024 | |
| VOR Vor Biopharma | Maintains: Outperform | $22 → $14 | $0.79 | +1,672.15% | 3 | Nov 8, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $90.44 | +17.20% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $14.30 | +25.87% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $26.15 | +588.34% | 9 | Sep 16, 2024 | |
| BLUE bluebird bio | Maintains: Outperform | $7 → $6 | $0.35 | +1,613.80% | 3 | Aug 15, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $3.72 | +115.05% | 1 | Jun 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $47.88 | +8.60% | 2 | May 9, 2024 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $84 | $32.28 | +160.22% | 1 | Oct 31, 2023 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $6 → $8 | $2.47 | +223.89% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $0.82 | +1,115.81% | 2 | Jun 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $2.21 | +442.99% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.50 | +892.26% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $2.29 | +1,122.71% | 1 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.87 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $5.66 | +59.15% | 1 | Oct 7, 2021 |
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $8 → $4
Current: $0.68
Upside: +488.24%
Vor Biopharma
Nov 8, 2024
Maintains: Outperform
Price Target: $22 → $14
Current: $0.79
Upside: +1,672.15%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $90.44
Upside: +17.20%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $14.30
Upside: +25.87%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $26.15
Upside: +588.34%
bluebird bio
Aug 15, 2024
Maintains: Outperform
Price Target: $7 → $6
Current: $0.35
Upside: +1,613.80%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $3.72
Upside: +115.05%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $47.88
Upside: +8.60%
Immunocore Holdings
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $32.28
Upside: +160.22%
Taysha Gene Therapies
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $2.47
Upside: +223.89%
Jun 28, 2023
Reiterates: Outperform
Price Target: $10
Current: $0.82
Upside: +1,115.81%
Jan 6, 2023
Upgrades: Outperform
Price Target: $12
Current: $2.21
Upside: +442.99%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $0.50
Upside: +892.26%
Jun 3, 2022
Initiates: Neutral
Price Target: $28
Current: $2.29
Upside: +1,122.71%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $1.87
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $5.66
Upside: +59.15%